We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ergon to Acquire Majority Stake in Elitech

By LabMedica International staff writers
Posted on 22 Nov 2010
Print article
Ergon Capital Partners (Brussels, Belgium), a mid-market private equity company, has signed an agreement to buy a majority stake in Elitech Group (Puteaux, France).

A leading independent manufacturer and distributor of in vitro diagnostic equipment, tests, and reagents, Elitech focuses on small to medium-sized, proximity, and emergency diagnostic laboratories. The Group is currently active in three segments of the diagnostics market: biochemistry, microbiology, and molecular diagnostics.

In the fiscal year ended March 31, 2010, Elitech Group reported proforma sales of US$125.7 million and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of $16.5 million.

Pierre Debiais, CEO of Elitech Group commented: "This is a strategically important step in the development of the Group. Ergon is a reputed investment institution, which will provide us with its expertise in the future transformation of the Group by bringing further professional qualities and capacity to the organization and by assisting us in making add-on acquisitions."

Ergon targets equity investment in companies located in France, Benelux, Italy, Spain, and Switzerland. Headquartered in Brussels, Ergon has offices in Paris, Milan, and Madrid. Ergon's investment philosophy is one of value creation in partnership with management, following an industrial strategy to generate long-term capital gains.

Related Links:

Elitech Group




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
Human Insulin CLIA
Human Insulin CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.